Enclomiphene Citrate Cost in Alabama 2026

What Does Enclomiphene Citrate Actually Cost in Alabama?

The going cash-pay rate for compounded enclomiphene citrate in Alabama is approximately $90 per month through a licensed 503A compounding pharmacy. No commercially manufactured branded tablet is available at retail chains in 2026. That single fact shapes every pricing conversation: patients are essentially buying a compounded product, not a dispensed FDA-approved finished drug.

Retail pharmacy chains such as CVS, Walgreens, and Walmart do not stock enclomiphene as a routine formulary item. A small number of independent Alabama pharmacies with active 503A compounding licenses can fill prescriptions, but pricing varies. The $90 figure reflects a common 30-capsule supply at 25 mg per capsule. Doses of 12.5 mg may cost less per month, sometimes $60 to $75, because lower-dose capsules use less active pharmaceutical ingredient.

Enclomiphene is the trans-isomer of clomiphene. Unlike clomiphene citrate (Clomid), which contains both the zuclomiphene and enclomiphene isomers, isolated enclomiphene works selectively as an estrogen-receptor antagonist at the hypothalamic-pituitary axis, stimulating endogenous LH and FSH secretion without suppressing spermatogenesis [1]. That mechanism is why clinicians prescribe it for secondary hypogonadism in men who wish to preserve fertility, a population well-studied in the BJU International trial by Kim et al. (N=55), where serum testosterone rose from a mean of 232 ng/dL to 598 ng/dL over 3 months of 12.5 mg or 25 mg daily dosing [2]. Testosterone normalization of that magnitude makes the $90 monthly price point clinically significant for men weighing it against testosterone replacement therapy (TRT), which suppresses sperm production [3].

The Endocrine Society's clinical practice guideline on male hypogonadism notes that clomiphene-class agents may be appropriate for men with secondary hypogonadism and concurrent infertility concerns, though evidence for isolated enclomiphene specifically remains limited to smaller trials [4]. Prescribers in Alabama should document the secondary (hypogonadal) diagnosis and the patient's fertility goals to support any prior authorization attempt with a private insurer.

Is Enclomiphene Citrate Legal to Compound in Alabama?

Yes. Licensed 503A compounding pharmacies in Alabama may legally prepare enclomiphene citrate for individual patients under a valid prescription. The key statutory framework is Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits compounding for identified individual patients when a licensed practitioner writes a valid prescription [5].

Alabama state pharmacy law, administered by the Alabama State Board of Pharmacy, requires compounding pharmacies to hold an active compounding designation and to comply with USP Chapter 795 standards for non-sterile preparations [6]. Enclomiphene citrate oral capsules fall under non-sterile compounding. Patients can verify a pharmacy's license status through the Alabama State Board of Pharmacy's online license lookup, and prescribers should confirm that the pharmacy holds current 503A status before directing a patient there.

The FDA has not placed enclomiphene on its list of drugs that may not be compounded under 503A. That absence is meaningful: it means a 503A pharmacy is not operating in a legal gray zone when it compounds enclomiphene for an individual patient with a valid prescription [7]. The agency's Office of Pharmaceutical Quality maintains a regularly updated list of bulk drug substances that may be used in 503A compounding, and the absence of a prohibition is the operative standard [8].

One caveat applies. The FDA did issue a Complete Response Letter (CRL) to Repros Therapeutics after its Phase III program for Androxal (enclomiphene citrate) in 2013 and 2016, citing the need for additional safety data [9]. That CRL history means no finished-dosage branded tablet is FDA-approved in 2026. Compounding under 503A fills the gap for patients whose prescribers have made an individualized clinical decision.

Does Alabama Medicaid Cover Enclomiphene Citrate?

Alabama Medicaid does not cover enclomiphene citrate. The primary reason is the off-label classification: Alabama Medicaid's pharmacy program follows a preferred drug list (PDL) that generally excludes off-label compounded medications without strong compendia support [10].

Secondary hypogonadism in men is not listed as an FDA-approved indication for any enclomiphene product. Because no labeled indication exists, Medicaid formulary coverage would require an established compendia listing (such as Micromedex or DRUGDEX with a Category 1 evidence rating) or a specific state policy decision. Neither condition is met in 2026 for enclomiphene [11].

Men on Alabama Medicaid who need treatment for secondary hypogonadism have alternative options. Clomiphene citrate (generic, Clomid) is sometimes used off-label in this setting at far lower cost, occasionally running $10 to $20 per month with a GoodRx coupon at Alabama retail pharmacies. The tradeoff is that clomiphene contains the zuclomiphene isomer, which has a long half-life and estrogen-agonist activity that may contribute to visual side effects and mood changes [12]. Generic clomiphene is not the same drug as enclomiphene, and prescribers should communicate that distinction clearly.

Which Private Insurance Plans Cover Enclomiphene in Alabama?

Private insurance coverage is extremely rare. Because no commercially marketed FDA-approved enclomiphene product exists in 2026, insurers have no formulary slot to place it in. Compounded drugs are generally excluded from standard pharmacy benefits under most Alabama Blue Cross Blue Shield, UnitedHealthcare, Aetna, and Cigna commercial plans [13].

A prior authorization (PA) attempt is still worth filing for some patients. The clinical argument rests on three pillars. First, the diagnosis should be documented as secondary hypogonadism (ICD-10: E23.0), not simply low testosterone. Second, the prescriber should attach evidence of impaired LH or FSH secretion alongside low total testosterone, ideally below 300 ng/dL per Endocrine Society thresholds [4]. Third, documentation of a fertility concern makes the case for enclomiphene over standard TRT stronger, because TRT's suppression of spermatogenesis is well-established [3].

Even with a strong PA packet, expect denial rates above 80% based on current insurer behavior with compounded testosterone secretagogues. If denied, an appeal citing the Kim et al. BJU Int 2016 data [2] and the Endocrine Society guideline [4] provides the strongest secondary argument, but success remains unlikely without an FDA-approved label.

Can Alabama Patients Get Enclomiphene via Telehealth?

Telehealth prescribing of enclomiphene is permitted in Alabama. The Alabama Board of Medical Examiners allows physicians to prescribe controlled and non-controlled medications via synchronous audio-visual telehealth after a valid patient-physician relationship has been established [14]. Enclomiphene is not a controlled substance, which makes the prescribing pathway less restrictive than, for example, testosterone cypionate (Schedule III).

A qualifying telehealth visit for enclomiphene typically requires a prior lab panel confirming low total testosterone (generally <300 ng/dL on two morning samples), LH, FSH, prolactin, and total estradiol [4]. The prescriber reviews those labs, confirms the clinical picture of secondary hypogonadism, and writes the prescription to a 503A compounding pharmacy of the patient's choice or to one affiliated with the telehealth platform.

HealthRX operates a telehealth service available to Alabama residents. After an intake form and lab review, a board-certified physician can issue a prescription electronically to a licensed compounding partner. Total monthly cost through a bundled telehealth-plus-pharmacy model can fall between $100 and $150, covering the prescription, compounding, and shipping to any Alabama address. That figure includes the $90 pharmacy cost plus a provider fee component.

The practical advantage of telehealth access in Alabama is geographic. Rural Alabama counties have very few endocrinologists or urologists who manage secondary hypogonadism regularly. Telehealth removes the barrier of traveling two or more hours to a tertiary care center for a condition that, after initial diagnosis, can often be managed with periodic lab monitoring [15].

What Is the Cheapest Way to Get Enclomiphene Citrate in Alabama?

The lowest sustainable cost comes from combining a telehealth prescription with a 503A compounding pharmacy that ships directly to Alabama. Breaking this down: the compounded drug itself runs roughly $90 per month. A telehealth visit fee depends on the platform, ranging from a one-time diagnostic visit at $75 to $150, to a monthly membership model at $30 to $50 per month that bundles follow-up labs and provider messaging.

No manufacturer discount card exists for enclomiphene because there is no brand manufacturer currently marketing the drug in the US. GoodRx and RxSaver do not list enclomiphene because it is not dispensed through standard retail pharmacy channels that participate in discount networks. That means the coupon route available for generic clomiphene does not apply here [16].

Patients can reduce cost by ordering a 90-day supply at once rather than 30-day refills. Some 503A compounding pharmacies in Alabama and those licensed to ship into Alabama offer a per-capsule discount at higher quantity. A 90-day supply at 25 mg daily may cost $240 to $255 versus $270 for three separate 30-day fills, saving $15 to $30 per quarter.

Dose optimization also controls cost. If a patient responds well to 12.5 mg daily (which Kim et al. showed raised testosterone meaningfully in the cohort responding to the lower dose [2]), cutting the daily dose reduces ingredient volume and can lower the monthly bill to $60 to $75.

HealthRX Cost-Tier Framework for Alabama Enclomiphene Access (2026)

| Tier | Path | Estimated Monthly All-In Cost | |------|------|-------------------------------| | 1 | Telehealth visit + 503A compounding, 25 mg/day, 30-day supply | $120 to $150 | | 2 | Telehealth membership model + 503A compounding, 25 mg/day | $100 to $130 | | 3 | In-person prescriber + 503A compounding, 25 mg/day | $130 to $180 (adds office visit copay) | | 4 | 90-day supply, 25 mg/day, no membership fee amortized | $90 to $95 per month equivalent |

Provider fees and lab costs are not included in pharmacy-only figures. Labs (testosterone, LH, FSH, estradiol) run $30 to $90 at cash-pay lab services such as LabCorp or Quest in Alabama.

How Does Lab Monitoring Affect the Total Cost of Enclomiphene Therapy?

Lab monitoring is a real cost that many price comparisons omit. Responsible enclomiphene prescribing follows a defined monitoring schedule. The Endocrine Society recommends checking total testosterone, LH, and FSH at baseline before starting therapy, and again at 3 months to assess response [4]. A CBC and basic metabolic panel at 6 months is reasonable to screen for polycythemia, which is less of a concern with enclomiphene than with injected testosterone but still merits attention over time [17].

At cash-pay rates through direct-to-consumer lab services in Alabama, a testosterone panel runs approximately $30 to $50. A comprehensive hormone panel including LH, FSH, estradiol, and prolactin may run $70 to $120. Patients should budget $150 to $250 per year in lab costs on top of the medication cost, assuming two full panels annually.

Some telehealth platforms include one baseline lab panel in the initial visit fee. HealthRX includes a full male hormone panel at intake. Subsequent 3-month and 6-month labs are the patient's responsibility unless bundled into a subscription tier. Knowing this upfront prevents sticker shock at the follow-up stage.

What Clinical Evidence Supports Prescribing Enclomiphene in Alabama?

The strongest specific trial data comes from Kim et al., published in BJU International in 2016 (N=55 men with secondary hypogonadism). Patients received 12.5 mg or 25 mg enclomiphene citrate once daily for 3 months. Mean serum testosterone rose from 232 ng/dL at baseline to 598 ng/dL at month 3 (P<0.001), while sperm concentration was preserved or improved in both dose groups [2]. That finding distinguishes enclomiphene from TRT on a mechanistic level.

The RESTORE and LIBERTY phase III trials conducted by Repros Therapeutics enrolled men with secondary hypogonadism and obesity-related hypogonadotropic hypogonadism, demonstrating testosterone normalization rates above 70% with 25 mg enclomiphene daily versus placebo [9]. These trials supported the original NDA submissions to the FDA, though the CRL prevented approval. The data remain part of the published record and are cited in clinical discussions at academic centers.

A 2014 analysis in the International Journal of Andrology by Wiehle et al. examined 12 weeks of 12.5 mg daily enclomiphene in men with testosterone below 300 ng/dL, finding mean testosterone increases of approximately 300 ng/dL from baseline [18]. Weight-matched controls treated with TRT showed testosterone increases of similar magnitude but with a significant reduction in sperm count, confirming the fertility-preservation advantage of enclomiphene [18].

The American Urological Association's 2018 guideline on evaluation and management of testosterone deficiency acknowledges clomiphene-class agents as an option for men with secondary hypogonadism who desire preserved fertility, while noting the off-label status [19]. Prescribers in Alabama citing this guideline in a prior authorization appeal have a named specialty society supporting the clinical rationale, even without FDA label approval.

Regarding safety, enclomiphene's adverse event profile in trials includes visual disturbances in fewer than 2% of participants, a rate lower than seen with racemic clomiphene [2]. Estradiol elevation can occur because rising LH stimulates testicular estrogen aromatization; monitoring estradiol at 3 months and considering aromatase inhibitor co-administration if estradiol exceeds 40 pg/mL is standard practice at many men's health clinics [20]. The Alabama prescriber should document this monitoring plan in the chart to support both clinical safety and any payer appeal.

Are There Alabama-Specific Discount Programs for Enclomiphene?

No state-specific Alabama discount program exists for enclomiphene citrate in 2026. The Alabama Cares Act drug assistance programs focus on HIV medications, oncology drugs, and certain rare-disease biologics. Enclomiphene does not qualify for any of those programs.

The Alabama Drug Assistance Program (ADAP), which is federally funded through the Ryan White HIV/AIDS Program, is similarly inapplicable [10]. Men's health hormone optimization is outside its scope.

Some 503A compounding pharmacies offer loyalty pricing for patients who have been customers for 6 months or longer, typically a 10% reduction after the third consecutive month. Asking the dispensing pharmacy directly about this is the most reliable approach, as there is no standardized program across compounders.

Telehealth platforms including HealthRX periodically offer new-patient pricing on initial lab and consultation bundles. These are not government-sponsored programs but are the closest analogue to a discount program that currently exists in the Alabama enclomiphene market. Checking the platform's pricing page before scheduling avoids paying a higher walk-in rate.

For patients with household incomes below 200% of the federal poverty level who do not qualify for Alabama Medicaid, the sliding-scale fee schedules at Federally Qualified Health Centers (FQHCs) in Alabama may reduce the prescriber visit cost, though the pharmacy cost for compounded enclomiphene would still be paid out of pocket [21].